|
Report No. : |
345971 |
|
Report Date : |
20.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
ZANCTOK PHARMACEUTICAL LABORATORIES |
|
|
|
|
Registered Office : |
F/5, S.I.T.E., Hyderabad |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1995 |
|
|
|
|
Legal Form : |
Partnership |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
|
|
|
|
No. of Employees : |
63 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Pakistan |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
ZANCTOK PHARMACEUTICAL LABORATORIES
|
Registered
Address & Factory |
|
F/5, S.I.T.E., Hyderabad, Pakistan |
|
Tel # |
92 (22) 3880525, 3880567 |
|
Fax # |
92 (22) 3880567 |
|
a. |
Nature of Business |
Manufacture & Marketing of
Pharmaceutical Products |
|
b. |
Year Established |
1995 |
|
c. |
National Tax # |
2197216 |
|
In Karachi at present |
|
Subject Company was established as a Partnership business in 1995 |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Muhammad Saleem Mr. Wazir Ali Lasi Mr. Noor Ali Sewani Mr. Qaim Ali |
Pakistani Pakistani Pakistan Pakistan |
F/5, S.I.T.E., Hyderabad, Pakistan F/5, S.I.T.E., Hyderabad, Pakistan F/5, S.I.T.E., Hyderabad, Pakistan F/5, S.I.T.E., Hyderabad, Pakistan |
Business Business Business Business |
Managing Partner Partner Partner Partner |
A. Subsidiary
None
B. Associated
Companies
-
Do -
(1) Subject Company is engaged in manufacture & marketing of
Pharmaceutical Products.
(2) It purchases raw material
against D/A, D/P basis.
(3) Its mainly import from India, China, Korea & Taiwan.
(4) Its’ major customers are Distribution Companies, Traders, Pharmacies
& Hospitals etc.
(5) Subject operates from caption leased factory premises of area
measuring 2,000 Sq.Yard which is
situated in industrial area.
(6) Subject employs about 63
persons in its set up.
|
Year |
In Pak Rupees |
|
2014 |
38,000,000/- (Estimated) |
|
The capacity and production of the company’s
plant is indeterminable as it is multi- product and involves various
processes of manufacture. |
(1) JUNGBUNZLAUER AUSTRIA,
GERMANY.
(2) ASHU INTERNATIONAL, INDIA.
(3) HERCULES CHEMICALS JIANGMEN CO.
LTD, CHINA.
Habib Bank Limited, Pakistan.
(2) Habib Metropolitan Bank Limited, Pakistan.
(3) Faysal Bank Limited, Pakistan.
(4) MCB Bank Limited, Pakistan.
(5) Allied Bank Limited, Pakistan.
Hyderabad Chamber of Commerce & Industry.(HCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 104.45 |
|
UK Pound |
1 |
Rs. 160.50 |
|
Euro |
1 |
Rs. 118.25 |
Subject Company was established in 1995 and is engaged in manufacture
& marketing of Pharmaceutical Products. Trade relations are reported as
fair. Subject can be considered for normal business dealings at usual trade
terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.64.82 |
|
|
1 |
Rs.100.12 |
|
Euro |
1 |
Rs.73.75 |
INFORMATION DETAILS
|
Analysis Done by
: |
HEE |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.